Laboratorio de Referencia Nacional de Infecciones Intrahospitalarias, Instituto Nacional de Salud, Lima, Perú.
Unidad de Intervenciones Estratégicas, Instituto Nacional de Salud, Lima, Perú.
Rev Peru Med Exp Salud Publica. 2021 Jan-Mar;38(1):113-118. doi: 10.17843/rpmesp.2021.381.5882. Epub 2021 Jun 25.
Resistance to carbapenems is a public health problem. This study presents the identification of carbapenemase enzymes in Enterobacteriaceae, Pseudomonas spp. and Acinetobacter spp. present in strains from 30 institutions that provide health services in Peru as part of the quality control process in diagnoses. Phenotypic confirmation and enzymatic identification were performed using the Blue CARBA test and the synergy test with phenylboronic acid and ethylenediaminetetraacetic acid/sodium mercaptoacetic acid discs. 185 strains with carbapenemases were identified: 78 in Enterobacteriaceae, 61 in P. aeruginosa and 46 in Acinetobacter spp. The types of carbapenemases identified were: blaKPC, blaNDM, blaIMP, blaVIM, blaOXA-23, blaOXA-24, blaOXA-51 and the blaVIM/IMP co-production. It is important to strengthen the promotion of the rational use of antimicrobials and epidemiological surveillance in the country's hospitals.
对碳青霉烯类药物的耐药性是一个公共卫生问题。本研究鉴定了来自秘鲁 30 家提供医疗服务机构的菌株中的肠杆菌科、假单胞菌属和不动杆菌属中存在的碳青霉烯酶,这是作为诊断质量控制过程的一部分。采用 Blue CARBA 试验和苯硼酸与乙二胺四乙酸/巯基乙酸钠联合药敏纸片试验进行表型确认和酶鉴定。共鉴定出 185 株产碳青霉烯酶菌株:肠杆菌科 78 株,铜绿假单胞菌 61 株,鲍曼不动杆菌 46 株。鉴定出的碳青霉烯酶类型包括:blaKPC、blaNDM、blaIMP、blaVIM、blaOXA-23、blaOXA-24、blaOXA-51 和 blaVIM/IMP 协同产生。加强国家医院对抗菌药物合理使用的推广和流行病学监测非常重要。